Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
RMD Open. 2023 Mar;9(1):e002898. doi: 10.1136/rmdopen-2022-002898.
RMD Open. 2023.
PMID: 36863753
Free PMC article.
Review.
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis.
van der Togt CJT, Ten Cate DF, den Broeder N, Rahamat-Langendoen J, van den Bemt BJF, den Broeder AA.
van der Togt CJT, et al.
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI175-SI179. doi: 10.1093/rheumatology/keac206.
Rheumatology (Oxford). 2022.
PMID: 35377422
Free PMC article.
Item in Clipboard
Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.
van der Togt CJT, Ten Cate DF, van den Bemt BJF, Rahamat-Langendoen J, den Broeder N, den Broeder AA.
van der Togt CJT, et al.
Rheumatology (Oxford). 2023 Apr 3;62(4):1627-1630. doi: 10.1093/rheumatology/keac486.
Rheumatology (Oxford). 2023.
PMID: 36000861
Free PMC article.
Item in Clipboard
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study).
van der Togt CJT, Verhoef LM, van den Bemt BJF, den Broeder N, Ter Heine R, den Broeder AA.
van der Togt CJT, et al.
Ther Adv Musculoskelet Dis. 2022 Dec 12;14:1759720X221142277. doi: 10.1177/1759720X221142277. eCollection 2022.
Ther Adv Musculoskelet Dis. 2022.
PMID: 36533097
Free PMC article.
Item in Clipboard
Disease activity-guided dose optimisation including discontinuation of TNF-inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study.
van der Togt CJT, den Broeder N, Boonstra MS, van der Maas A, den Broeder AA, van Herwaarden N.
van der Togt CJT, et al.
Rheumatology (Oxford). 2024 Feb 12:keae103. doi: 10.1093/rheumatology/keae103. Online ahead of print.
Rheumatology (Oxford). 2024.
PMID: 38346712
Item in Clipboard
Cite
Cite